Simplify Logo

Full-Time

Senior Manager

Etmf Management

Posted on 1/31/2024

Tango Therapeutics

Tango Therapeutics

51-200 employees

Develops targeted cancer therapies using CRISPR

Data & Analytics
Hardware
Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Category
Executive Support
Administrative & Executive Assistance
Risk & Compliance
Legal & Compliance
Required Skills
Communications
Management
Google Cloud Platform
PowerPoint/Keynote/Slides
Requirements
  • Life sciences degree or certification in a related allied health field
  • 3-5 years' experience with clinical trials (e.g., study coordinator, regulatory operations) and electronic TMF document management experience
  • Understanding of GCP and regulatory requirements as well as a working knowledge of clinical research documents, their contents and purpose
  • Demonstrated proficiency with MS Office skills such as Outlook, Word, Excel, PowerPoint, and SharePoint
Responsibilities
  • Maintain effective communication with project teams, CRO staff, and vendors throughout study start-up, maintenance, and close-out
  • Support study document filing into the trial TMF
  • Review and ensure compliance and oversight of TMF plans
  • Perform routine quality checks of documents uploaded into the TMF across trials, and ensure findings are documented and resolved in a timely manner
  • Respond to inquiries regarding TMF management and contents
  • Attend departmental and study-specific meetings and discussions, as required
  • Run routine TMF reports and monitor for completeness and trends
  • May provide TMF training to new team members
  • Perform general administrative tasks
  • Complete other study document-related tasks as required by the study teams

Tango Therapeutics is developing novel cancer medicines using DNA sequencing and CRISPR-based target discovery to create breakthrough therapies that target specific tumor vulnerabilities, including loss of tumor suppressor gene function, multiple oncogenic drivers, and immune evasion, leveraging the principle of synthetic lethality. The company's approach focuses on expanding the reach of genetically targeted therapies to take direct aim at specific tumors.

Company Stage

IPO

Total Funding

$537M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

10%

1 year growth

23%

2 year growth

84%
INACTIVE